DoD Prostate Cancer, Idea Development Award | W81XWH 21 PCRP IDA

Opportunity Information: Apply for W81XWH 21 PCRP IDA

The DoD Prostate Cancer Research Program (PCRP) FY21 Idea Development Award is a research grant opportunity designed to fund bold, genuinely new concepts in prostate cancer that could materially move the field forward. The core expectation is innovation: proposals should introduce a fresh paradigm, challenge established thinking, or approach a persistent problem from a new angle, including by leveraging unique patient populations or applying multidisciplinary and data science driven methods. Work that mainly extends existing published findings in an incremental way is not what this mechanism is meant to support. In addition to being creative, projects must clearly aim for impact by directly addressing at least one of the FY21 PCRP Overarching Challenges, with a convincing explanation of how the results could matter in both the near term and long term for research progress and/or patient care.

Unlike many mechanisms that strongly depend on extensive preliminary results, this award encourages (but does not require) preliminary data because it is structured to make room for higher risk, higher reward ideas. If applicants do include unpublished preliminary data, it needs to come from the Principal Investigator (PI) or members of the research team. Even without preliminary data, applications are still expected to be grounded in strong scientific rationale built from logical reasoning and a critical reading of the literature. To strengthen rigor and real world relevance, applicants are urged to incorporate practices such as authenticating cell lines, applying strong statistical rigor in animal and epidemiological studies, and adding experiments that test clinical relevance and translatability, including validation in patient cohorts when appropriate. If a project relies on special resources (such as datasets, biorepositories, clinical populations, or other enabling infrastructure), the program encourages letters of support that confirm access and availability.

A notable feature is the New Investigator category, which is meant to bring early career researchers into the prostate cancer space or help them establish independence with an ambitious idea. New Investigators are evaluated with different personnel focused criteria, but they are required to include at least one experienced prostate cancer collaborator with a demonstrated track record of funding and publications. The application must explain how the collaboration will work in practice, why it is likely to succeed, and how it fills gaps in the New Investigator PI’s expertise to better answer the proposed research question. Applicants are also encouraged to include letters of collaboration describing the collaborator’s role and commitment.

The program welcomes multidisciplinary, multi institutional projects, provided the team puts forward a clear management plan describing how partners will communicate, coordinate milestones, share data, and integrate results. For multi institutional efforts, the application must also include an intellectual property plan that anticipates and resolves potential institutional barriers, including ownership or material transfer issues that could slow collaboration. This emphasis reflects the program’s interest in projects that can move efficiently from concept to meaningful outputs without administrative bottlenecks.

Human subjects research is allowed under this opportunity, but clinical trials are explicitly not allowed. The DoD uses a specific definition of a clinical trial: any study where human subjects are prospectively assigned to an intervention to evaluate effects on health related outcomes. In contrast, correlative studies connected to an existing clinical trial are specifically encouraged, which signals that the program values translational work that can extract new knowledge from ongoing clinical efforts without initiating a new intervention study. For any clinical research involving prospective recruitment or use of human subjects, the project must be deemed no greater than minimal risk by the IRB of record and by the U.S. Army Medical Research and Development Command (USAMRDC) Office of Research Protections, Human Research Protection Office (HRPO). Local IRB approval is not required at the time of application submission, but applicants should plan for additional DoD regulatory review timelines, typically at least 2 to 3 months for HRPO review. If multiple institutions are involved in human subjects research, a single IRB plan is required, identifying the lead institution responsible for the master protocol, consent form, and serving as the central regulatory point of contact.

Animal research is also permitted, with parallel oversight requirements. In addition to local IACUC review, DoD funded animal studies must be reviewed and approved by the Animal Care and Use Review Office (ACURO). As with human subjects research, IACUC approval is not required at submission, but applicants should build in the additional regulatory time, commonly at least 3 to 4 months for ACURO processes. The announcement also stresses reproducibility and transparent reporting standards, pointing applicants to widely recognized best practices such as randomization, blinding, appropriate sample size estimation, and clear data handling procedures, along with the ARRIVE guidelines and broader reporting recommendations for preclinical research.

From a funding and administrative perspective, awards under this announcement are issued as assistance agreements, meaning they may be either grants or cooperative agreements. The deciding factor is how much substantial involvement the DoD anticipates during the project. If the agency expects no substantial involvement, the award is typically a grant; if active collaboration or intervention by the agency is anticipated, it will be structured as a cooperative agreement, and that involvement will be spelled out during negotiations. The anticipated maximum direct cost for a project is $750,000 across the full period of performance. Programmatically, the DoD projected roughly $36 million total to support about 30 awards, with funding dependent on federal availability and the outcome of scientific and programmatic review. Awards were expected to be made by September 30, 2022, and the FY21 funds were anticipated to remain available for use through September 30, 2027.

The opportunity also sits within a broader DoD research context focused on advanced disease and translation. Applicants are encouraged to consider the recommendations of the congressionally mandated Metastatic Cancer Task Force, particularly if their ideas can accelerate clinical and translational research for advanced or recurrent cancers while still staying within the mechanism’s boundaries (notably, no clinical trials). Finally, the proposed work must be relevant to active duty Service Members, Veterans, military beneficiaries, and/or the American public, and the program strongly encourages partnerships between military or VA institutions and non military organizations to combine expertise, infrastructure, and access to distinctive clinical populations.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 05, 2021.
• Applicants must submit their applications by Sep 23, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 30 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: